Abstracts tagged "prevention and rheumatoid arthritis (RA)"

Abstract Number: 507 • 2018 ACR/ARHP Annual Meeting
Echocardiographic Markers of Right Ventricle Dysfunction in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study
José R. Azpiri-López¹, Dionicio A. Galarza-Delgado², Iris J. Colunga-Pedraza³, Jose A. Davila-Jimenez⁴, Estefania E. Abundis-Marquez⁴, Andres H. Guillen-Lozoya⁴, Francisco J. Torres-Quintanilla⁴, Aldo Valdovinos-Bañuelos⁴, Ray Ramos-Cázares⁴, Raymundo Vera-Pineda⁴, Jesus A. Cardenas-de la Garza⁴, Rosa I. Arvizu-Rivera⁴ and Adrián Martínez-Moreno⁴, ¹Cardiology, Hospital Universitario, UANL, Monterrey, Mexico, ²Chief of Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, ³Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, ⁴Hospital Universitario, UANL, Monterrey, Mexico
Background/Purpose: Screening for cardiovascular (CV) disease in patients with rheumatoid arthritis (RA) remains controversial, however, there is agreement in considering echocardiography as the most immediate…
Abstract Number: 508 • 2018 ACR/ARHP Annual Meeting
Non-Invasive Evaluation of Left Atrial Pressure in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study
José R. Azpiri-López¹, Dionicio A. Galarza-Delgado², Iris J. Colunga-Pedraza³, Jose A. Davila-Jimenez⁴, Estefania E. Abundis-Marquez⁴, Andres H. Guillen-Lozoya⁴, Francisco J. Torres-Quintanilla⁴, Aldo Valdovinos-Bañuelos⁴, Ray Ramos-Cázares⁴, Raymundo Vera-Pineda⁴, Jesus A. Cardenas-de la Garza⁴, Rosa I. Arvizu-Rivera⁴ and Adrián Martínez-Moreno⁴, ¹Cardiology, Hospital Universitario, UANL, Monterrey, Mexico, ²Chief of Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, ³Rheumatology, Hospital Universitario, UANL, Monterrey, Mexico, ⁴Hospital Universitario, UANL, Monterrey, Mexico
Background/Purpose: In the last several years a higher prevalence of heart failure has been described in Rheumatoid arthritis (RA) patients, particularly heart failure with preserved…
Abstract Number: 1910 • 2018 ACR/ARHP Annual Meeting
Impact of Cyclic Citrullinated Peptide Autoantibody Level on Progression to Rheumatoid Arthritis Among CCP-Positive Patients without RA in a Clinical Setting
Julia Ford¹, Xinyi Liu², Allison Marshall¹, Alessandra Zaccardelli¹, Maria Prado¹, Charlene Wiyarand³, Bing Lu⁴, Elizabeth Karlson², Peter Schur¹, Kevin D. Deane⁵ and Jeffrey A. Sparks², ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, University of Colorado Denver, Aurora, CO
Background/Purpose: Autoantibodies to cyclic citrullinated peptide (CCP) are present years prior to the onset of clinical RA. This observation was based on blood bank samples from individuals who later developed…
Abstract Number: 24 • 2016 ACR/ARHP Annual Meeting
Modifiable Rheumatoid Arthritis Factors and Impact on Cardiovascular Risk
Katherine Liao¹, Carol J. Etzel^2,3, Jeffrey D. Greenberg⁴, Hongshu Guan⁵, Joel Kremer⁶ and Daniel H. Solomon⁷, ¹Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ²Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴New York University School of Medicine, New York, NY, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶The Center for Rheumatology, Albany Medical College, Albany, NY, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) is a major source of morbidity and mortality in RA, but current management goals follow general population recommendations without tailoring based…
Abstract Number: 452 • 2016 ACR/ARHP Annual Meeting
The Efficacy of Motivational Counselling and SMS-Reminders on Daily Sitting Time in Patients with Rheumatoid Arthritis: A Randomised Controlled Trial
Tanja Thomsen¹, Mette Aadahl², Nina Beyer³, Merete Lund Hetland⁴, Katrine Loeppenthin¹, Julie Midtgaard⁵, Robin Christensen⁶, Mikkel Østergaard⁷, Poul Jennum⁸ and Bente Appel Esbensen¹, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²Research Centre for Prevention and Health, Rigshospitalet, Denmark, Copenhagen, Denmark, ³Musculoskeletal Rehabilitation Research Unit, Bispebjerg and Frederiksberg Hospitals, Denmark, Copenhagen, Denmark, ⁴Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ⁵University Hospitals Centre for Health Research, Rigshospitalet, Copenhagen, Denmark, ⁶Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁷Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁸Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Rigshospitalet, Denmark, Copenhagen, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) are more sedentary than the general population, which can have serious health consequences. Reducing sedentary behaviour (SB) and increasing…
Abstract Number: 2643 • 2016 ACR/ARHP Annual Meeting
Risk Factors of Pneumocystis Jiroveci Pneumonia (PJP) in Patients with RA and Sulfasalazine As a Possible Protective Agent
Shinji Motojima¹, Tamao Nakashita², Akira Jibatake¹, Akira Yoshida¹ and Yoshiki Yamamoto¹, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is a serious complication during the treatment in patients with variety of rheumatic disease. Postmarketing surveillance of infliximab and etnercept…
Abstract Number: 3028 • 2016 ACR/ARHP Annual Meeting
A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA
Danielle M. Gerlag^1,2, Mary Safy³, Karen I. Maijer⁴, Sander W. Tas⁵, Mirian Starmans-kool⁶, A. van Tubergen⁷, M. Janssen⁸ and Paul-Peter Tak⁹, ¹Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Current address: GSK,Clinical Unit Cambridge,R&D Projects Clinical Platforms & Sciences, Cambridge, United Kingdom, ³Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Dept. of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology, Orbis Medical Center, Geleen-Sittard, Netherlands, ⁷Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁸Rheumatology Dept, Rijnstate Hospital, Arnhem, Netherlands, ⁹currently: , Ghent University, Ghent, Belgium, Ghent, Belgium
Background/Purpose: The development of clinical signs and symptoms of seropositive rheumatoid arthritis (RA) is often preceded by a phase of systemic autoimmunity. This offers a…
Abstract Number: 2210 • 2015 ACR/ARHP Annual Meeting
Immunological Dysregulation and Inadequate Hypoxia Adaptation – HIF-Stabilization As Possible Prevention of Fracture Healing Disorders in RA or Immune-Suppressed Patients
Annemarie Lang^1,2,3, Sarah Fuegener², Paula Hoff^1,2, Katharina Schmidt-Bleek⁴, Timo Gaber^1,2 and Frank Buttgereit², ¹German Rheumatism Research Center (DRFZ), Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ³Berlin-Brandenburg School of Regenerative Therapies (BSRT), Berlin, Germany, ⁴Julius Wolff Institut, Charité University Medicine, Berlin, Germany
Background/Purpose: Patients suffering from rheumatoid arthritis (RA) are often affected by fracture-healing complications such as increased fracture healing time or non-unions. There is not much…
Abstract Number: 1846 • 2014 ACR/ARHP Annual Meeting
The Association Between Hydroxychloroquine Treatment and Cardiovascular Morbidity Among Rheumatoid Arthritis Patients
Michael Shapiro¹ and Yair Levy², ¹Haim Lebanon 55, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Internal Medicine E, Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Accelerated atherosclerosis and cardiovascular disease are the main causes of mortality in Rheumatoid Arthritis (RA). The anti-malarial drug Hydroxychloroquine (HCQ) has long been used…
Abstract Number: 1428 • 2014 ACR/ARHP Annual Meeting
Comparison of Application of the European Society Cardiology, Adult Treatment Panel III, and ACC/AHA Guidelines for Cardiovascular Disease Prevention in a French Cohort of Rheumatoid Arthritis
Martin Soubrier¹, Zuzana Tatar², Maxime Chevreau³, Bruno Pereira⁴, Laure Gossec⁵, P Gaudin⁶ and Maxime Dougados⁷, ¹COMEDRA trial group, Paris, France, ²Centre Jean Perrin, Clermont Ferrand, France, ³Rheumatology, CHU Sud Hospital, Grenoble, France, ⁴Clinical research department, Clermont-Ferrand, France, ⁵Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, ⁶CHU Hôpital Sud, Grenoble, France, ⁷RAID working group for EULAR, Zurich, Switzerland
Background/Purpose Cardiovascular risk (CVR) is increased in RA and should be evaluated annually. EULAR recommends using the SCORE equation to calculate risk, after applying a…
Abstract Number: 1163 • 2014 ACR/ARHP Annual Meeting
Predictors of Cholesterol and Lifestyle Discussions in Rheumatoid Arthritis Visits: Impact of Perceived RA Control and Comparison with Other Prevention Topics
Christie M. Bartels¹, Joanna Wong², Heather Johnson³, Katya Voelker⁴ and Maureen Smith⁵, ¹Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Tufts University School of Medicine, Boston, MA, ³Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Univ of Wisconsin School of Medicine and Public Health, Madison, AA, ⁵Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Experts recommend discussing modifiable cardiovascular disease (CVD) risk factors in RA visits. We examined the predictors of discussions about cholesterol and or lifestyle (weight,…
Abstract Number: 1709 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patient Cardiovascular Disease Prevention Experiences: Qualitative Analysis and Implications
Christie M. Bartels¹, Sarah Tweddell², Barbara Bowers³, Elizabeth Jacobs⁴ and Tonya Roberts³, ¹Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW School of Medicine and Public Health, Madison, WI, ³UW School of Nursing, Madison, WI, ⁴Internal Medicine, UW School of Medicine and Public Health, Madison, WI
Background/Purpose: Although rheumatoid arthritis (RA) increases cardiovascular disease (CVD) risk, RA patients receive less CVD preventive care than peers. We previously showed gaps in lipid…
Abstract Number: 414 • 2013 ACR/ARHP Annual Meeting
High Prevalence Of Obesity Among Early and Established Rheumatoid Arthritis
Ines Colmegna¹, Maria Celia Bazan Bardales², Susan J. Bartlett³ and Carol A. Hitchon⁴, ¹Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ²Rheumatology, McGill University, Montreal, QC, Canada, ³Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁴Rheumatology, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatoid arthritis (RA) is characterized by early, accelerated atherosclerosis leading to increased disability, morbidity and mortality. Inflammation and traditional cardiovascular (CVD) risk factors contribute…
Abstract Number: 1244 • 2012 ACR/ARHP Annual Meeting
Group Cycling in Rheumatoid Arthritis: Positive Effects On Aerobic Capacity and Blood Pressure
Lars Ångström¹, Kristina Hörnberg¹ and Solveig Wållberg Jonsson², ¹Department of Public Health and Clinical Medicine/Rheumatology, University of Umeå, Umeå Sweden, Dept of Rheumatology, Umeå, Sweden, ²Department of Public Health and Clinical Medicine, Dept of Rheumatology, Umeå, Sweden
Background/Purpose: Cardiovascular disease (CVD) is increased in rheumatoid arthritis (RA) (1). Strong evidence shows that exercise reduces the CVD risk in the general population (2).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].